妊娠期肝内胆汁淤积症孕妇应用思美泰与优思弗联合治疗对患者肝功能及围生儿预后的影响

Effects of Combined Treatment with Transmentil and Ursofalk on Liver Function and Perinatal Prognosis in Pregnant Women with Intrahepatic Cholestasis of Pregnancy

目的:分析妊娠期肝内胆汁淤积症(ICP)采取思美泰联合优思弗治疗对患者肝功能及围生儿预后的影响。方法:随机抽签法将144例ICP患者分为思美泰组、优思弗组与联合组,每组48例,分别给予思美泰、优思弗单药治疗及两者联合干预。评价三组疗效、治疗前后肝功能指标、血清白介素-17 (IL-17)、IL-18水平变化、母婴结局及不良反应。结果:联合组治疗总有效率91.67%,均显著高于思美泰组的75.00%及优思弗组的77.08% (P 0.05)。结论:ICP应用思美泰联合优思弗治疗疗效较好,能明显改善患者肝功能,降低血清IL-17、IL-18水平,减少不良围生儿预后。

Objective: To analyze the effects of combined treatment with Transmentil and Ursofalk on liver function and perinatal prognosis in pregnant women with intraperitoneal cholestasis of pregnancy (ICP). Methods: 144 patients with ICP were randomly divided into the Transmentil group, the Ursofalk group and the combined group, 48 cases in each group. The three groups were treated with Transmentil, Ursofalk and combination of the two, respectively. The curative effect, liver function indicators before and after treatment, changes in levels of serum interleukin-17 (IL-17) and IL-18, maternal and neonatal outcomes and adverse reactions in all groups were evaluated. Results: The total effective rate of the combined group (91.67%) was significantly higher than that in the Transmentil group (75.00%) or the Ursofalk group (77.08%) (P 0.05). Conclusion: The curative effect of combined treatment with Transmentil and Ur-sofalk for ICP is good. It can significantly improve the liver function, reduce serum IL-17 and IL-18 levels, and reduce poor perinatal prognosis.